Cardiac allograft vasculopathy optical coherence tomography
Cardiac allograft vasculopathy Microchapters |
Differentiating Cardiac allograft vasculopathy from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Cardiac allograft vasculopathy optical coherence tomography On the Web |
American Roentgen Ray Society Images of Cardiac allograft vasculopathy optical coherence tomography |
FDA on Cardiac allograft vasculopathy optical coherence tomography |
CDC on Cardiac allograft vasculopathy optical coherence tomography |
Cardiac allograft vasculopathy optical coherence tomography in the news |
Blogs on Cardiac allograft vasculopathy optical coherence tomography |
Directions to Hospitals Treating Cardiac allograft vasculopathy |
Risk calculators and risk factors for Cardiac allograft vasculopathy optical coherence tomography |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aarti Narayan, M.B.B.S [2]; Raviteja Guddeti, M.B.B.S. [3]
Overview
In 2010, U.S FDA approved coronary optical cohorence tomography (OCT) as a new catheter based intra-vascular imaging modality with a resolution higher than intravascular ultrasound (IVUS). OCT uses near infra-red light and constructs images from the reflected light which is in the same phase (i.e cohorent) with the emitted light. This eliminated the interference from scattered light, thereby producing images with higher resolution.